Lyudmila Bazhenova, MD, discusses the FDA’s expanded approval of taletrectinib for ROS1-positive non–small cell lung cancer.
|Articles|November 13, 2014
- NSCLC (Issue 5)
- Volume 5
- Issue 1
The Role of Chemotherapy in the Treatment of Lung Cancer
Author(s)Benjamin P. Levy, MD
Benjamin P. Levy, MD, comments on the role of chemotherapy in the treatment of lung cancer.
Advertisement
Benjamin P. Levy, MD, director, Thoracic Medical Oncology, assistant professor, Icahn School of Medicine, Mount Sinai Health System, comments on the role of chemotherapy in the treatment of lung cancer.
Read about the importance of a multidisciplinary team in the treatment of lung cancer > >
Articles in this issue
almost 12 years ago
Veliparib Shows Potential in Squamous Cell NSCLCalmost 12 years ago
IDO Inhibitors May Augment Immunotherapy in NSCLCalmost 12 years ago
The Future of Squamous Cell Lung Cancer Treatmentalmost 12 years ago
Multidisciplinary Teams in NSCLC Important for Optimal Patient Carealmost 12 years ago
The Challenges of Treating Lung Canceralmost 12 years ago
Early Detection and Molecular Testing Evolving for NSCLCAdvertisement
Related to this article
During a live event, Mary Jo Fidler, MD, and participants discussed how an intermediate-risk regimen, insurance resistance, and limited experience with trilaciclib shape neutropenia prevention in extensive-stage disease.
For Hispanic Heritage Month, Narjust Florez, MD, discusses lung cancer risk, biomarker testing, and trial access in Hispanic and Latinx patients.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
3
MC001 Receives FDA Fast Track Designation in Pancreatic Cancer
4
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
5